Description:
The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working Group of the Association for Molecular Pathology Clinical Practice Committee are to define the key attributes of PGx alleles recommended for clinical testing and a minimum set of variants that should be included in clinical PGx genotyping assays. The CYP2C9 project and manuscript provides recommendations for a minimum panel of variant alleles (Tier 1) and an extended panel of variant alleles (Tier 2) that will aid clinical laboratories when designing assays for CYP2C9 testing.
Learning Objectives:
- To identify sequence variants that define CYP2C9 star (*) allele haplotypes.
- To review CYP2C9 pharmacogenetics and highlight clinically relevant medications that are metabolized by CYP2C9.
- To describe the AMP PGx Working Group and examine the reported CYP2C9 'Tier 1 and 2' recommended alleles.
Practice Guideline Available Here
 |  |
|---|---|
| Speaker Stuart A. Scott, PhD, FACMG | Moderator Yuan Ji, PhD, FACMG |
Duration: 1 hr
Level of Instruction: Basic
Date Recorded: September 5, 2019
Continuing Education Credit Information
CE Credit for this course has expired.Note: Members of AMP can access this webinar at no cost. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
